ANTI-IL-36R ANTIBODY AND USE THEREOF
Provided are an anti-IL-36R antibody and a use thereof. In particular, a mouse, chimeric or humanized antibody binding to IL-36R or an antigen binding fragment thereof is provided; further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, as well as an expression vector and host cell used to express the antibody or the antigen-binding fragment thereof. In addition, a preparation method and a use method for the antibody or the antigen-binding fragment thereof are provided, comprising treatment and prevention of relevant IL-36/IL-36R-mediated diseases and disorders..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 25. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LONG XI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
AU2022291974 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001240188 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001240188 | ||
| 003 | DE-627 | ||
| 005 | 20240426160139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001240188 | ||
| 035 | |a (EPA)AU2022291974 | ||
| 035 | |a (EPA)84526886 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LONG XI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ANTI-IL-36R ANTIBODY AND USE THEREOF |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-25, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
| 520 | |a Provided are an anti-IL-36R antibody and a use thereof. In particular, a mouse, chimeric or humanized antibody binding to IL-36R or an antigen binding fragment thereof is provided; further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, as well as an expression vector and host cell used to express the antibody or the antigen-binding fragment thereof. In addition, a preparation method and a use method for the antibody or the antigen-binding fragment thereof are provided, comprising treatment and prevention of relevant IL-36/IL-36R-mediated diseases and disorders. | ||
| 650 | 4 | |a tec | |
| 650 | 4 | |a G01N: Investigating or analysing materials by determining their chemical or physical properties (measuring or testing processes other than immunoassay, involving enzymes or microorganisms c12m, c12q) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a XU HONGJIANG |e verfasserin |4 aut | |
| 700 | 0 | |a SHI WEI |e verfasserin |4 aut | |
| 700 | 0 | |a WANG LIANGLIANG |e verfasserin |4 aut | |
| 700 | 0 | |a LU ZHENZHEN |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 25. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:25 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84526886/publication/AU2022291974A1?q=AU2022291974 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 25 |c 01 | ||